AMGN
Amgen Inc
NASDAQ: AMGN · HEALTHCARE · DRUG MANUFACTURERS - GENERAL
$377.35
-1.34% today
Updated 2026-09-11
Market cap
$204.01B
P/E ratio
23.75
P/S ratio
5.36x
EPS (TTM)
$15.89
Dividend yield
2.56%
52W range
$262 – $447
Volume
2.5M
WallStSmart proprietary scores
71
out of 100
Grade: B
Buy
Investment rating
8.0
Growth
A3.5
Quality
D9.0
Profitability
A+4.0
Valuation
C5/9
Piotroski F-Score
Moderate
0.6
Altman Z-Score
Distress
—
Industry rank
—
View all highly rated stocks (75+) →251 stocks currently score above 75
Price targets
Analyst target
$355.19
-5.87%
12-Month target
$352.30
-6.64%
Intrinsic (DCF)
$285.44
Margin of safety
-32.20%
4 Strong Buy10 Buy16 Hold2 Sell2 Strong Sell
Price chart
Stock snapshot
Strengths
+ Profit margin 23.00% — above average
+ ROE 74.80% — strong efficiency
+ Free cash flow $3.49B — positive
Risks
- Altman Z 0.56 — distress zone
- 32.20% above intrinsic value
- Debt/equity 4.90x — high leverage
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM | 2026 (E) |
|---|---|---|---|---|---|---|
| Revenue | $26.32B | $28.19B | $33.42B | $36.74B | $38.09B | $39.1B |
| Net income | $6.55B | $6.72B | $4.09B | $7.71B | $2.38B | — |
| EPS | — | — | — | — | $15.89 | $23.45 |
| Free cash flow | $8.79B | $7.36B | $10.39B | $8.10B | $3.49B | — |
| Profit margin | 24.89% | 23.83% | 12.24% | 20.99% | 23.00% | — |
Recent insider activity
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| 2026-08-13 | KHOSLA, RACHNA | Sale | 1,252 | — |
| 2026-08-13 | KHOSLA, RACHNA | Buy | 1,252 | $162.60 |
| 2026-08-11 | KHOSLA, RACHNA | Sale | 2,000 | $412.57 |
Peer comparison
Smart narrative
Amgen Inc trades at $377.35. representing a P/E of 23.75x trailing earnings. Our Smart Value Score of 71/100 indicates the stock is good. The company scores 5/9 on the Piotroski F-Score. With an Altman Z-Score of 0.56, it sits in the distress. TTM revenue stands at $38.09B. with profit margins at 23.00%. Our DCF model estimates intrinsic value at $285.44.
Frequently asked questions
What is Amgen Inc's stock price?
Amgen Inc (AMGN) trades at $377.35, on a P/E of 23.8x and a P/S of 5.4x. Those multiples show what the market is paying for each dollar of earnings and sales, which is the real starting point for judging whether the price is reasonable.
Is Amgen Inc overvalued?
Amgen Inc carries a Smart Value Score of 71/100 (Grade B), which we rate Buy. That score blends growth, quality, and valuation into one read. On valuation specifically, our conservative DCF puts intrinsic value at $285.44 against the $377.35 price, so on cash flow terms the market is paying a premium for Amgen Inc's growth. The Buy rating reflects that growth and quality, while the DCF flags that the price already assumes a lot.
What is the price target of Amgen Inc (AMGN)?
The 12-month analyst consensus target is $355.19, about 5.9% below the current $377.35. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.
What is the future stock price of AMGN by 2030?
Our research-backed model puts the 2030 base case at $247.06, built from revenue projections, a growth-adjusted P/S multiple, net debt, and share dilution. It is a scenario rather than a prediction, and the bull and bear cases around it matter more than the single number when you are sizing a position.
What is the intrinsic value of Amgen Inc (AMGN)?
Our DCF model estimates intrinsic value at $285.44, a -32.2% margin of safety versus today's $377.35. Intrinsic value is what the projected cash flows are worth today. A negative reading means the price is running ahead of that conservative estimate, leaving little downside cushion if growth slows.
What is Amgen Inc's revenue?
Amgen Inc's trailing twelve-month revenue is $38.09B, and our model projects it reaching about $54.20B by 2030. Revenue scale anchors the valuation multiples and shows whether growth is reaching the top line, so it is best read alongside margin and growth trends to see if that revenue is getting more profitable over time.
Altman Z-Score?
Amgen Inc's Altman Z-Score is 0.56, which places it in the distress. The Altman Z-Score gauges bankruptcy risk from profitability, leverage, and asset efficiency, and a higher reading points to lower financial distress risk.
Company info
SectorHEALTHCARE
IndustryDRUG MANUFACTURERS - GENERAL
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio5.36x
ROE74.80%
Beta0.43
50D MA$398.78
200D MA$359.17
Shares out0.54B
Float0.54B
Short ratio—
Avg volume2.5M
Performance
1 week-13.70%
1 month-9.12%
3 months+7.65%
YTD+15.29%
1 year+36.53%
3 years—
5 years—